Ratings CellSource Co., Ltd.

Equities

4880

JP3423580004

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-09 am EDT			5-day change	1st Jan Change
1,489 ^JPY	-0.87%		-3.75%	+16.42%

2023	Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2023.	CI
2023	MEDERI Inc. announced that it has received funding from CellSource Co., Ltd.	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's high margin levels account for strong profits.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.

Weaknesses

The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 49.25 times its estimated earnings per share for the ongoing year.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is highly valued given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	ESG Refinitiv
CELLSOURCE CO., LTD.	+16.42%	191M	-
SONIC HEALTHCARE LIMITED	-17.08%	8.39B	B+
RADNET, INC.	+54.36%	3.74B	C+
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-37.54%	2.55B	B-
SYNLAB AG	-9.63%	2.48B	-
DR. LAL PATHLABS LIMITED	-13.43%	2.32B	B-
NEOGENOMICS, INC.	-5.75%	1.93B	C-
FLEURY S.A.	-18.46%	1.6B	A-
DIAN DIAGNOSTICS GROUP CO.,LTD.	-36.41%	1.28B	C+
METROPOLIS HEALTHCARE LIMITED	+2.19%	1.08B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes